abstract |
The invention relates to compounds of the general formula (I) wherein R<1> is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, -S-lower alkyl, -S(O)2-lower alkyl, -N(R)-(CH2)n-N(R)2,-O-(CH2)n-N(R)2,-N(R)2, or a cyclic tertiary amine of the group which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker -O(CH2)n-; R<2> is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R<3>/R<3'> is, independently from each other, hydrogen or lower alkyl; R<4> is independently from each other halogen, trifluoromethyl or lower alkoxy; R<5> is hydrogen or lower alkyl; R is, independently from each other, hydrogen or lower alkyl; X is -C(O)N(R)- or -N(R)C(O)-; Y is -O-, -S-, -SO2-, - or -N(R)-; n is 1,2,3 or 4; and m is 0,1 or 2; and to pharmaceutically acceptable acid addition salts thereof. They have a good affitity to the NK1 receptor and they are therefore suitable in the treatment of diseases, related to this receptor. |